Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Japan-based Kyoto University, iPS Academia Japan and iPierian have entered into a series of intellectual property agreements to create a unified, worldwide patent estate covering induced pluripotent stem cell (iPSC) technology.
Subscribe to our email newsletter
iPierian has assigned the iPSC patent estate it previously acquired from Bayer Schering Pharma in 2008 to Kyoto University. In turn, Kyoto University and iPS Academia Japan have granted iPierian non-exclusive worldwide rights to its combined patent estate relating to iPSC technology for use in drug discovery and development.
iPierian CEO Michael Venuti said that these agreements further strengthen and capitalise on iPierian’s position to pursue iPSC-enabled drug discovery.
iPS Academia Japan is an affiliate of Kyoto University which manages and utilises patents and other intellectual properties held/controlled by Kyoto University in the field of iPSC technologies.
iPierian is a biopharmaceutical company focused on the industrialisation of iPSC technology.